This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
GUPTA V, MUNJAL JS, JHAJJ P, JHAJJ S, JAIN R. Obesity and Atrial Fibrillation: A Narrative Review. Cureus. 2022;14(11):e31205.Search in Google Scholar
DE LORENZO A, GRATTERI S, GUALTIERI P, CAMMARANO A, BERTUCCI P, DI RENZO L. Why primary obesity is a disease? J Transl Med. 2019;17(1):169.Search in Google Scholar
LIN X, LI H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne). 2021;12:706978.Search in Google Scholar
ANAM, M., MAHARJAN, S., AMJAD, Z., ABAZA, A., VASAVADA, AM., SADHU, A., et al. Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs). Cureus, 14(12), e32610.Search in Google Scholar
WORLD HEALTH ORGANIZATION. Obesity and overweight. Geneva: World Health Organization; 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overSearch in Google Scholar
CENTERS FOR DISEASE CONTROL AND PREVENTION. National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. 27 September 2022. Available at: https://www.cdc.gov/Search in Google Scholar
SINGH G, KRAUTHAMER M, BJALME-EVANS M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022;70(1):5–13.Search in Google Scholar
MOHAMMED MS, SENDRA S, LLORET J, BOSCH I. Systems and WBANs for Controlling Obesity. J Health Eng. 2018;2018:1564748.Search in Google Scholar
PANUGANTI KK, NGUYEN M, KSHIRSAGAR RK. Obesity. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.Search in Google Scholar
THE LANCET DIABETES ENDOCRINOLOGY. Let's talk about obesity. Lancet Diabetes Endocrinol. 2023;11(4):217.Search in Google Scholar
WIECHERT M, HOLZAPFEL C. Nutrition Concepts for the Treatment of Obesity in Adults. Nutrients. 2021 Dec 30;14(1):169.Search in Google Scholar
YUMUK, V., TSIGOS, C., FRIED, M., SCHINDLER, K., BUSETTO, L., MICIC, D., et al. European Guidelines for Obesity Management in Adults. Obesity facts, 8(6), 402–424.Search in Google Scholar
COHEN JB, GADDE KM. Weight Loss Medications in the Treatment of Obesity and Hypertension. Curr Hypertens Rep. 2019;21(2):16.Search in Google Scholar
SON JW, KIM S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J. 2020;44(6):802–818.Search in Google Scholar
AJOOLABADY, A., LIU, S., KLIONSKY, DJ., LIP, GYH., TUOMILEHTO, J., KAVALAKATT, S., et al. ER stress in obesity pathogenesis and management. Trends in pharmacological sciences, 43(2), 97–109.Search in Google Scholar
LEE KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract. 2001;54 Suppl 2:S29–S33.Search in Google Scholar
ARCARO, G., ZAMBONI, M., ROSSI, L., TURCATO, E., COVI, G., ARMELLINI, F., BOSELLO, O. et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity. International journal of obesity and related metabolic disorders: Journal of the International Association for the Study of Obesity, 23(9), 936–942.Search in Google Scholar
POIRIER, P., GILES, TD., BRAY, GA., HONG, Y., STERN, JS., PI-SUNYER, FX. et al. American Heart Association, & Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism (2006). Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation, 113(6), 898–918.Search in Google Scholar
YUDKIN JS, STEHOUWER CD, EMEIS JJ, COPPACK SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972–978.Search in Google Scholar
CIGOLINI M, TARGHER G, BERGAMO ANDREIS IA, TONOLI M, AGOSTINO G, DE SANDRE G., Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16(3):368–374.Search in Google Scholar
MOHAMED-ALI, V., GOODRICK, S., RAWESH, A., KATZ, D. R., MILES, J. M., YUDKIN, J. S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. The Journal of clinical endocrinology and metabolism.1997; 82(12), 4196–4200.Search in Google Scholar
RIDKER PM. Novel risk factors and markers for coronary disease. Adv Intern Med. 2000;45:391-418.Search in Google Scholar
ROCHA VZ, LIBBY P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6:399–409.Search in Google Scholar
ROSS R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138(pt 2):S419–S420.Search in Google Scholar
IACOBELLIS G. Epicardial and pericardial fat: close, but very different. Obesity (Silver Spring). 2009;17(4):625; author reply 626-7.Search in Google Scholar
POWELL-WILEY, TM., POIRIER, P., BURKE, LE., DESPRÉS, JP., GORDON-LARSEN, P., LAVIE, CJ., et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21), e984–e1010.Search in Google Scholar
ROSITO, GA., MASSARO, JM., HOFFMANN, U., RUBERG, FL., MAHABADI, AA., VASAN, RS., O'DONNELL, CJ., et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation.2008; 117(5), 605–613.Search in Google Scholar
FOX, CS., MASSARO, JM., HOFFMANN, U., POU, KM., MAUROVICH-HORVAT, P., LIU, CY., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation.2007; 116(1), 39–48.Search in Google Scholar
VEGA GL, ADAMS-HUET B, PESHOCK R, WILLETT D, SHAH B, GRUNDY SM. Influence of body fat content and distribution on variation in metabolic risk. J Clin Endocrinol Metab. 2006;91(11):4459-4466.Search in Google Scholar
POU, KM., MASSARO, JM., HOFFMANN, U., VASAN, RS., MAUROVICH-HORVAT, P., LARSON, MG., et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation2007; 116(11), 1234–1241.Search in Google Scholar
TAGUCHI, R., TAKASU, J., ITANI, Y., YAMAMOTO, R., YOKOYAMA, K., WATANABE, S., et al., Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis. 2001;157(1): 203–209.Search in Google Scholar
JEONG, JW., JEONG, MH., YUN, KH., OH, SK., PARK, EM., KIM, YK., et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circulation journal : official journal of the Japanese Circulation Society.2007; 71(4):536–539.Search in Google Scholar
MONTAN PD, SOURLAS A, OLIVERO J, SILVERIO D, GUZMAN E, KOSMAS CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019;7(16):393.Search in Google Scholar
GADDE KM. Current pharmacotherapy for obesity: extrapolation of clinical trials data to practice. Expert Opin Pharmacother. 2014;15(6):809–822.Search in Google Scholar
COULTER AA, REBELLO CJ, GREENWAY FL. Centrally Acting Agents for Obesity: Past, Present, and Future. Drugs. 2018;78(11):1113–1132.Search in Google Scholar
PATEL DK, STANFORD FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130(2):173–182.Search in Google Scholar
YANOVSKI SZ, YANOVSKI JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311(1):74–86.Search in Google Scholar
RODGERS RJ, TSCHÖP MH, WILDING JP. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5(5):621–626.Search in Google Scholar
MORDES JP, LIU C, XU S. Medications for weight loss. Curr Opin Endocrinol Diabetes Obes. 2015;22(2):91-7.Search in Google Scholar
VOSBURG, RW., EL CHAAR, M., EL DJOUZI, S., DOCIMO, S., JR, CHOI, D., LAMASTERS, T., et al. Literature review on antiobesity medication use for metabolic and bariatric surgery patients from the American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. Surgery for obesity and related diseases: official journal of the American Society for Bariatric Surgery.2022; 18(9):1109–1119.Search in Google Scholar
FUJIOKA K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring). 2015;23 Suppl 1:S7-11.Search in Google Scholar
WOODARD K, LOUQUE L, HSIA DS. Medications for the treatment of obesity in adolescents. Ther Adv Endocrinol Metab. 2020;11:2042018820918789.Search in Google Scholar
VELAZQUEZ A, APOVIAN CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018; 1411(1):106–119.Search in Google Scholar
LEI XG, RUAN JQ, LAI C, SUN Z, YANG X. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2021;29(6):985–994.Search in Google Scholar
TORGERSON JS, HAUPTMAN J, BOLDRIN MN, SJÖSTRÖM L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004 Mar;27(3):856]. Diabetes Care. 2004;27(1):155–161.Search in Google Scholar
APOVIAN CM. Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future Cardiol. 2016; 12(2):129–138.Search in Google Scholar
KÜHNEN, P., CLÉMENT, K., WIEGAND, S., BLANKENSTEIN, O., GOTTESDIENER, K., MARTINI, LL., et al. Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. The New England journal of medicine. 2016;375(3), 240–246.Search in Google Scholar
TCHANG BG, TARAZI MS, ARAS M, SHUKLA AP. An update on pharmacotherapeutic strategies for obesity. Expert Opin Pharmacother. 2021;22(10):1305–1318.Search in Google Scholar
HEYMSFIELD, SB., COLEMAN, LA., MILLER, R., ROOKS, DS., LAURENT, D., PETRICOUL, O., et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA network open, 4(1), e2033457.Search in Google Scholar
HUGHES TE, KIM DD, MARJASON J, PROIETTO J, WHITEHEAD JP, VATH JE. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-8.Search in Google Scholar
GRUNVALD E, SHAH R, HERNAEZ R, CHANDAR AK, PICKETT-BLAKELY O, TEIGEN LM, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225.Search in Google Scholar
GIUGLIANO, D., MAIORINO, MI., BELLASTELLA, G., LONGO, M., CHIODINI, P., ESPOSITO, K. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes, obesity & metabolism.2019; 21(11):2576–2580.Search in Google Scholar
BONORA, E., FRIAS, JP., TINAHONES, FJ., VAN, J., MALIK, RE., YU, Z., et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11. Diabetes, obesity & metabolism.2021;23(10), 2242–2250.Search in Google Scholar
DOGGRELL S. A. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert opinion on investigational drugs. 2023;32(5), 355–359.Search in Google Scholar
